gp75 DNA vaccine

The gp75 DNA vaccine is an experimental cancer immunotherapy designed to induce an immune response against melanoma by encoding the melanosomal membrane glycoprotein known as gp75 or tyrosinase-related protein-1 (TRP-1). This antigen is highly expressed in melanoma cells. The mechanism of action involves delivering plasmid DNA encoding the tumor-associated antigen (gp75/TRP-1), leading to *in vivo* expression of the antigen and subsequent activation of both cellular and humoral immune responses targeting melanoma cells. Some versions use self-replicating alphavirus replicons to enhance immunogenicity and break tolerance against this self-antigen[3][2][7]. The primary indication is for melanoma treatment or prevention[1][4].

Other names

Melanoma DNA vaccine gp75 DNA encoding melanosomal membrane glycoproteinsTRP-1/gp75 DNA vaccinetyrosinase-related protein-1 (TRP-1) DNA vaccine